You are here

InheRET: A SaaS solution to identify patients at increased risk for hereditary disease.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R42CA239842-02A1
Agency Tracking Number: R42CA239842
Amount: $1,989,229.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 102
Solicitation Number: PA19-271
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-10
Award End Date (Contract End Date): 2022-08-31
Small Business Information
3470 GREENLEAF CT
Ann Arbor, MI 48105-3503
United States
DUNS: 081229434
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DAVID KEREN
 (844) 464-3738
 dkeren@inheret.com
Business Contact
 LYNN MCCAIN
Phone: (734) 417-5884
Email: lmccain@inheret.com
Research Institution
 UNIVERSITY OF MICHIGAN
 
1600 HURON PARKWAY
ANN ARBOR, MI 48109-5001
United States

 Nonprofit College or University
Abstract

PROJECT SUMMARY
This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of
patients at increased risk for hereditary disease, adding patient navigation features and customizable database
entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0
followed by pilot testing in 5 diverse clinics. InheRETandapos;s aim is to quickly and easily identify individuals at
increased risk for hereditary diseases enabling them to access downstream care, reducing morbidity and
mortality. InheRETandapos;s unique features reduces clinical ascertainment barriers, streamlines workflows and
enhances profitability within health systems. The aims for this project are to complete in silico (computer
generated) testing of the cognitive computing engine of InheRET followed retrospective testing and finally, pilot
testing in a variety of clinical settings to determine if any additional changes are needed to the product prior to
commercialization. In addition, we will expand the integration of the InheRET program with an EPIC electronic
health record system, providing hard and/or soft alerts for providers as patient reports become available.
Success will be determined if we achieve 100% concordance with the in silico testing (i.e. the cognitive
computing engine functions correctly), 98% concordance with clinical determinations in the clinical pilot testing,
and 100% concordance in the integration testing (all patient reports are appropriately and seamlessly routed to
the proper medical records).
Our primary objective is to produce an accurate, easy-to-use and understandable report to ensure patients
who may unknowingly harbor inherited genetic mutations are identified, thereby enabling them to access
genetic counselors and testing along with appropriate downstream care. While both patient and physician
reports are provided, the physician reports will be enhanced by providing recommended genes for testing with
streamlined ordering processes. By doing so, patients can reduce their risk of disease, receive tailored
treatment if they incur disease, and reduce overall mortality.PROJECT NARRATIVE
This project is to expand the InheRET Inherited Risk Evaluation Tool to include recommendations for testing of
patients at increased risk for hereditary disease, adding patient navigation features and customizable database
entries for healthcare providers. This will include the development, integration and testing of InheRET 3.0,
followed by a pilot study in 5 diverse clinics. InheRETandapos;s aim is to quickly and easily identify individuals at
increased risk for hereditary diseases enabling them to access downstream care, reducing morbidity and
mortality. InheRETandapos;s unique features reduces clinical ascertainment barriers, streamlines workflows and
enhances profitability within health systems.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government